Hong Kong Journal of Nephrology
Volume 9, Issue 2 , Pages 77-81 , October 2007

Conversion from Recombinant Human Erythropoietin to Once Every 4 Weeks Darbepoetin Alfa for Treatment of Renal Anemia in CAPD Patients

References 

  1. Levin A , Thompson CR , Ethier J , Carlisle EJ , Tobe S , Mendelssohn D , et al.   Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin . Am J Kidney Dis . 1999;34:125–134
  2. Harnett JD , Foley RN , Kent GM , Barre PE , Murray D , Parfrey PS . Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors . Kidney Int . 1995;47:884–890
  3. Wolcott DL , Marsh JT , La Rue A , Carr C , Nissenson AR . Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients . Am J Kidney Dis . 1989;14:478–485
  4. Evans RW , Rader B , Manninen DL , Cooperative Multicenter EPO Clinical Trial Group  . The quality of life of hemodialysis recipients treated with recombinant human erythropoietin . JAMA . 1990;263:825–830
  5. Al-Ahmad A , Rand WM , Manjunath G , Konstam MA , Salem DN , Levey AS , et al.   Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction . J Am Coll Cardiol . 2001;38:955–962
  6. Winearls CG , Oliver DO , Pippard MJ , Reid C , Downing MR , Cotes PM . Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis . Lancet . 1986;2:1175–1178
  7. Eschbach JW , Egrie JC , Downing WR , Browne JK , Adamson JW . Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial . N Engl J Med . 1987;316:73–78
  8. Egrie J , Browne JK . Development and characterization of novel erythropoiesis stimulating protein (NESP) . Nephrol Dial Transplant . 2001;16(Suppl 3):3–13
  9. MacDougall IC , Gray SJ , Elston O , Breen C , Jenkins B , Browne J , et al.   Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients . J Am Soc Nephrol . 1999;10:2392–2395
  10. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, et al  Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients . Kidney Int . 2002;62:2167–2175
  11. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, et al  Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency . Kidney Int . 2001;60:741–747
  12. Nissenson AR , Swan SK , Lindberg JS , Soroka SD , Beatey R , Wang C , et al.   Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients . Am J Kidney Dis . 2002;40:110–118
  13. MacDougall IC , Matcham J , Gray SJ , NESP 960245/246 Study Group  . Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis . Nephrol Dial Transplant . 2003;18:576–581
  14. Locatelli F , Canaud B , Giacardy F , Martin-Malo A , Baker N , Wilson J . Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo) . Nephrol Dial Transplant . 2003;18:362–369
  15. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, et al  Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients . Nephrol Dial Transplant . 2004;19:1224–1230
  16. Hertel J , Locay H , Scarlata D , Jackson L , Prathikanti R , Audhya P . Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR) . Am J Nephrol . 2006;26:149–156
  17. Carrera F , Oliveira L , Maia P , Mendes T , Ferreira C . The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis . Nephrol Dial Transplant . 2006;21:2846–2850
  18. Jadoul M , Vanrenterghem Y , Foret M , Walker R , Gray SJ , Darbepoetin Alfa 20000144 Study Group  . Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients . Nephrol Dial Transplant . 2004;19:898–903
  19. Theodoridis M , Passadakis P , Kriki P , Panagoutsos S , Yannatos E , Kantartzi K , et al.   Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients . Perit Dial Int . 2005;25:564–569
  20. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt KU, Horl WH, et al  Practical guidelines for the use of NESP in treating renal anaemia . Nephrol Dial Transplant . 2001;16(Suppl 3):22–28

PII: S1561-5413(08)60004-6

doi: 10.1016/S1561-5413(08)60004-6

Hong Kong Journal of Nephrology
Volume 9, Issue 2 , Pages 77-81 , October 2007

Article Tools